Our Berlin bureau chief, Philip Oltermann, stories on the rollout of Novavax’s Covid-19 vaccine in Germany:
Germany will supply its inhabitants a brand new protein-based Covid-19 vaccine comparable to standard flu jabs this week, within the hope of swaying a sizeable minority that is still sceptical of the novel mRNA know-how utilized in probably the most generally used vaccines.
About 1.4m doses of the Nuvaxovid vaccine developed by the US biotech firm Novavax are to reach in Germany this week, the nation’s well being minister, Karl Lauterbach, confirmed final Friday. An extra 1m doses are to reach the week after, with the German authorities’s complete order for the yr 2022 amounting to 34m doses.
Novavax’s product has till now solely been utilized in Indonesia and the Philippines, however was permitted to be used within the EU final December. It’s nonetheless awaiting authorisation within the US, as some issues concerning the firm’s manufacturing capability persist.
In contrast to the novel mRNA vaccines produced by Pfizer/BioNTech and Moderna or viral vector made by AstraZeneca and Johnson & Johnson, Nuvaxovid is a protein subunit vaccine. It accommodates a non-infectious part on the floor of the Sars-CoV-2 virus, which induces a protecting immune response when the physique’s immune cells come into contact with it.
Novavax introduced final Junethat its vaccine had confirmed greater than 90% efficient towards symptomatic infections with the Alpha variant, in trials together with practically 30,000 volunteers within the US and Mexico.
The corporate says its product is equally efficient towards the Delta and Omicron variants, particularly after a booster shot administered six months after the second jab. Germany’s Paul Ehrlich Institute notes that the information proving the vaccine’s efficacy towards extra infectious variants stays restricted.
Surveys in Germany recommend a substantial curiosity within the Novavax jab among the many 19.8 million individuals within the nation who’ve to this point declined to take a jab towards Covid-19. Out of 4,000 unvaccinated hospital employees surveyed in Berlin, 1,800 expressed an curiosity within the protein-based vaccine.
Within the northern states of Decrease Saxony, the well being ministry mentioned 6,000 individuals had put their title on a ready checklist for Nuvaxovid by early February.
Some scientists query whether or not the brand new vaccine will show a sport changer in a rustic whose general vaccination charge has been flatlining round 75% for months. Lars Korn, co-author of a present survey of anti-vaxxer attitudes performed by the College of Erfurt, instructed public broadcaster ZDF that two-thirds of respondents would proceed to utterly reject any type of vaccination.